In the BioHarmony Drug Report Database
Saxagliptin
Onglyza (saxagliptin) is a small molecule pharmaceutical. Saxagliptin was first approved as Onglyza on 2009-07-31. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against dipeptidyl peptidase 4. Onglyza’s patents are valid until 2028-11-30 (FDA).
Trade Name
|
Onglyza |
|---|---|
Common Name
|
saxagliptin |
ChEMBL ID
|
CHEMBL2103745 |
Indication
|
type 2 diabetes mellitus |
Drug Class
|
Dipeptidyl aminopeptidase-IV inhibitors |
Image (chem structure or protein)